Cardiotoxicity & Immune Checkpoint Inhibitors (ICIs)

Although cardiac complications are not common, they could be accompanied with high morbidity and mortality. Experimental approaches such as using corticosteroids are becoming a part of guidelines for managing cardiac irAEs. However, a unique algorithm for diagnosis and management is necessary, especially in myocarditis cases.
Eftekhar et al. 2021 Expert Review of Anticancer Therapy 21(11): 1211-1228

These therapies portend a potentially fatal form of cardiotoxicity. Cardiotoxicity was defined as Cancer Therapeutics-related Cardiac Dysfunction (CTRCD) development, with an absolute left ventricular ejection fraction reduction of >10%, to a value <53%. Baseline diasto…